CRISPR Therapeutics AG (CRSP) Profit Margins
Over the twelve months to 2026-06-30, CRISPR Therapeutics AG (CRSP) had operating margin -3990.0%, net margin -3368.7%, free cash flow margin -2772.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRSPCRISPR Therapeutics AGFollow CRSP — free
—
Price chart with a free account
- Market cap
- 4.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | 88.9% | — | 64.9% | — | — | — | |
| Operating margin | -1319.3% | -157.7% | -5087.8% | 16.1% | -49295.5% | 40.8% | -56190.4% | -60.0% | -1250.4% | -18933.6% | -3990.0% | |
| Net margin | -448.8% | -166.7% | -5281.1% | 23.1% | -48520.9% | 41.3% | -54271.7% | -41.4% | -981.5% | -16569.8% | -3368.7% | |
| FCF margin | -1129.5% | -190.0% | -3169.4% | 17.3% | -35705.7% | 50.0% | -44484.9% | -72.7% | -387.7% | -9855.5% | -2772.7% |
USD billions · SEC XBRL
CRISPR Therapeutics AG — questions
- What is CRISPR Therapeutics AG's operating margin?
- -3990.0% over the twelve months to 2026-06-30.
- What is CRISPR Therapeutics AG's net profit margin?
- -3368.7% over the twelve months to 2026-06-30.
Every figure on this page comes from CRISPR Therapeutics AG's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.